Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the various short- and long-term side effects of antiretroviral therapy for HIV, highlighting issues like dyslipidemia and hypertension, but reports no new clinical results.

This case study describes a severe instance of iatrogenic Cushing's syndrome induced by gamma-hydroxybutyric acid, exacerbated by combined use of betamethasone and anabolic steroids, in an HIV-positive patient on cobicistat-containing therapy.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

In this study, reversible ageusia in a patient was strongly suggested to be caused by losartan, with potential implications for angiotensin receptor involvement in taste disturbance.

This chapter reviews common drug-related and systemic disorder-induced alopecias, focusing on their epidemiology, causes, symptoms, diagnosis, and treatment, but reports no new findings.

This study found that injecting drug users attending an oral substitution therapy center often experience skin lesions, which negatively impact their psychosocial health and quality of life.

Raltegravir may cause hair loss in some patients.

This case report describes a patient with HIV who experienced overlapping symptoms of primary and secondary syphilis and showed clinical and serological improvement after treatment with benzathine penicillin and antiretroviral drugs.

This research reported that STAT5 activation in the dermal papilla plays a crucial role in triggering anagen entry during post-developmental hair follicle cycling.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

This article reviews the relationship between the skin and the immune system and discusses how skin manifestations can indicate immunodeficiencies but reports no new research findings.

This study found that dermatological manifestations in HIV-positive individuals, such as infectious and non-infectious dermatoses, were significantly associated with CD4 T cell count.

This article describes how HIV-related skin disorders vary in presentation among pigmented skin types and highlights challenges in their diagnosis due to atypical disease manifestations.

The document concludes that skin and nail changes can indicate various underlying health conditions.

Chronic kidney disease can cause hair loss, which may be related to zinc deficiency or certain medications, and sometimes hair grows back when the underlying issue is treated.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

This study found that low power red laser therapy, combined with antiretroviral drug efavirenz, significantly reduces HIV-1 infection in TZM-bl cells to undetectable levels.

In this bibliometric study, researchers analyzed 96 publications from 2000 to 2022 to identify trends in HIV-1 capsid inhibitor research, highlighting the USA as a leading contributor and emphasizing the importance of molecular studies and drug discovery in advancing antiretroviral therapy.

This case report documents a woman with HIV who developed severe hair loss after starting lopinavir-ritonavir, which improved upon switching to a different antiretroviral drug.

This review discusses the role of skin manifestations as early markers and prognostic indicators of HIV infection in children but reports no new clinical results.

This study observed that while PrEP was effective among transgender women if taken, adherence was low, especially among those at higher risk.

This study identified several gonadal hormone drugs, including toremifene citrate, tamoxifen citrate, and clomiphene citrate, that effectively inhibited filovirus entry in a pseudovirus model.

In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.

This study found a high prevalence of sexually transmitted infections, particularly anogenital warts and syphilis, among HIV-infected adults in Serbia, underscoring the importance of education on safe sex practices.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

This review discusses various applications of nanoemulsions in drug delivery and reports no new clinical results; it highlights the patents that cover these applications.

This study reported that an alkaloid isolated from E. alba leaves inhibited HIV-1 reverse transcriptase activity with minimal cytotoxicity, suggesting its potential as an antiviral agent.

This review discusses spironolactone's new roles in tumor immunosurveillance, DNA repair inhibition, and viral infection suppression, highlighting its potential to extend uses beyond traditional applications, but reports no clinical results.